Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

Fig. 6

Alternative splicing in targeted therapy resistance. SRPK inhibitors enhance immune sensitivity by enhancing the expression of antigen-presenting MHCI and MHCII molecules and the recruitment of splenocytes. The deletion of PTBP1 can enhance MHC II expression and disrupt T cell homeostasis, and hnRNP A1 assists T lymphocyte recognition of melanoma cells

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us